Table 2.
Response to systemic therapy
| Number treated (n = 55) | Best response by RECIST 1.1, n (%) |
Median PFS (95% CI), months | |||||
|---|---|---|---|---|---|---|---|
| Complete response | Partial response | Stable disease | Progressive disease | Not evaluable | |||
| Doxorubicin based | 34 | 0 | 4 (12) | 15 (44) | 12 (22) | 3 (9) | 3 (0.9-4) |
| Pazopanib | 16 | 0 | 0 | 3 (19) | 9 (56) | 4 (25) | 1 (0-2) |
| Gemcitabine based | 13 | 0 | 2 (15%) | 4 (31) | 6 (46) | 1 (8) | 3 (1-5) |
| Sunitinib | 10 | 0 | 3 (30) | 2 (20) | 4 (40) | 1 (10) | 4 (1-7) |
| Dacarbazine | 9 | 0 | 0 | 2 (22) | 5 (56) | 2 (22) | 2 (NA) |
| Trabectedin | 7 | 0 | 0 | 1 (14) | 6 (86) | 0 | 1 (0.3-4) |
| Crizotinib | 5 | 0 | 0 | 1 (20) | 4 (80) | 0 | 2 (0.9-3) |
| Checkpoint inhibitor | 5 | 0 | 0 | 2 (40) | 3 (60) | 0 | 2 (0-6) |
| Ifosfamide | 5 | 0 | 0 | 0 | 4 (80) | 1 (20) | 1 (NA) |
CI, confidence interval; NA, not applicable; PFS, progression-free survival.